FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APP	OMB APPROVAL								
	OMB Number:	3235-0287								
	Estimated average burden									
- 1	houre per rechence:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hutson Nancy J</u>					2. Issuer Name and Ticker or Trading Symbol Clearside Biomedical, Inc. [ CLSD ]									tionship of all applic	,					
(Last) (First) (Middle) C/O CLEARSIDE BIOMEDICAL, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/10/2021									Officer (give title below)			Other (s below)	pecify		
900 NORTH POINT PARKWAY, SUITE 200					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) ALPHARETTA GA 30005													ie) X	,						
(City)		(State)	(Zip)																	
		Tak	ole I - Nor	n-Deriv	vativ	e Se	curities	s Ac	quired, D	isp	osed o	f, or Be	neficia	lly (	Owned					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date		Date,	Transaction Disposed Code (Instr. 5)		ties Acquire I Of (D) (Ins		4 and Securitie Benefici		s ally ollowing	Form	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	7	Amount	(A) or (D)	Price		Transact (Instr. 3 a	tion(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr 8)				6. Date Exercisab Expiration Date (Month/Day/Year)		of Securities		ies g Security	De Se	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares							
Stock Option (right to buy)	\$3.11	06/10/2021			A		25,000		(1)	06	6/09/2031	Common Stock	25,000		\$0.00	25,000	0	D		

## **Explanation of Responses:**

1. The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 10, 2022.

## Remarks:

/s/ Brian F. Leaf, Attorney-in-

06/11/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $Note: File \ three \ copies \ of \ this \ Form, \ one \ of \ which \ must \ be \ manually \ signed. \ If \ space \ is \ insufficient, see \ Instruction \ 6 \ for \ procedure.$ 

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).